

Amendments to the Claims:

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-16 (previously canceled).

17. (currently amended) A method for treating a subject with a Parkinsonian-type neurodegenerative disorder, comprising:

administering to said subject ~~a biologically effective amount of at least one α_{1B} adrenergic receptor antagonist, wherein administration of said antagonist tempers the severity of the disorder or the symptoms associated therewith a compound capable of blocking activation of α_{1B} adrenergic receptors.~~

Claims 18-21 (canceled)

22. (New) The method of claim 17, wherein the at least one α_{1B} adrenergic receptor antagonist is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, niguldipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidined.

24. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is terazosin.

25. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is prazosin.

26. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is 5 methylurapidil.

Appl. No. 10/052,589
Amdt. dated: November 9, 2004
Reply to Office Action of May 19, 2004

27. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is WB 4101.

28. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is niguldipine.

29. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is HEAT.

30. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is indoramine,

31. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is coryanthine.

32. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is spierone.

33. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is benoxathian.

34. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is spriorxatrine.

35. (New) The method of claim 22, wherein the at least one α 1B adrenergic receptor antagonist is chloroethylclonidined.

36. (New) A method for treating a subject with a neurodegenerative disorder that involves epileptic seizures, comprising:

administering to said subject a compound that binds to and blocks activation of α_1B adrenergic receptors, wherein administration of said compound lessens the severity of the disorder or the symptoms associated therewith.

37. (New) The method of claim 36 wherein said compound is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, nifedipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidine

38. (New) The method of claim 36, wherein the compound is terazosin.

39. (New) A method for treating a subject with a tryptophan hydroxylase-deficiency disorder, comprising:

administering to said subject a compound that binds to and blocks activation of α_1B adrenergic receptors, wherein administration of said compound lessens the severity of the disorder or the symptoms associated therewith.

40. (New) The method of claim 39 wherein said compound is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, nifedipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidine